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Angiotensin-Converting Enzyme
Inhibitors, Beta-Blockers, and
Mortality in Systolic Heart Failure
We read with interest the study by Johnson et al. (1). We believe that
one of the key findings of this study was the relatively low rates of
angiotensin-converting enzyme inhibitor (ACEI) angiotensin recep-
tor blocker (ARB) and beta-blocker (BB) use in heart failure (HF)
patients discharged from the hospital within three months, at 44.3%
and 20.9%, respectively, from 1999 to 2000. Furthermore, only 11.3%
of these patients received both an ACEI/ARB and a BB. The
inclusion in this study of HF patients with preserved left ventricular
systolic function (LVSF), or diastolic HF, may partially account for
the low rates of utilization of these medications. The current Amer-
ican College of Cardiology/American Heart Association (ACC/
AHA) HF guidelines do not have a recommendation to use either
ACEI/ARB or BB in patients with diastolic HF. Lack of appropriate
use of ACEI/ARB and BB in HF patients with impaired LVSF or
systolic HF indicates poor quality of care and is clearly associated with
poor outcomes. Although there is pathophysiological rationale for use
of ACEI/ARB and BB in patients with diastolic HF (2), lack of use
of these drugs in diastolic HF is neither poor quality of care nor is it
associated with poor outcomes. We believe that HF quality improve-
ment programs should focus on increasing the use of ACEI and BB
in patients with systolic HF, and studies of quality and outcomes of
HF care should classify patients based on their LVSF. Furthermore,
ARBs are not currently recommended in systolic HF unless patients
have an absolute contraindication to ACEI (2). The U.S. Centers for
Medicare and Medicaid Services in its Seventh Scope of Work (2002
to 2005) identified use of ACEI, not ARB, as a quality indicator for
HF care for Medicare beneficiaries (3).
We also note with interest an apparent lack of survival benefit of
combined use of ACEI/ARB and BB on one-year mortality as
compared to therapy with ACEI/ARB alone (1). Most large random-
ized controlled trials of BBs in systolic HF enrolled patients who were
already receiving an ACEI. These studies showed that use of a BB
resulted in an additional 35% reduction in mortality in subjects
receiving both drugs compared with those receiving an ACEI alone
(4). The rate of BB use in patients with systolic HF is low (5), and we
are concerned that the finding of lack of survival benefit of BBs in HF
as shown in the study by Johnson et al. (1) might be perceived by some
clinicians as evidence that results of clinical trials do not necessarily
translate into real-life patients.
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REPLY
Drs. Thornton and Ahmed have identified one important message
from our population cohort study (1). We agree that beta-blockers
and angiotensin-converting enzyme (ACE) inhibitors/receptor
blockers were underutilized in heart failure (HF) patients in
Alberta, Canada (1), and elsewhere (2–5). We found that adjusted
one-year mortality was lower in seniors hospitalized for HF who
were prescribed beta-blockers (18.2%; 95% confidence interval
[CI] 14.2 to 22.2) or ACE inhibitor/receptor blockers (22.3%;
95% CI 20.9 to 23.7) within three months of hospital discharge
than in those with no prescriptions (29.9%; 95% CI 28.8 to 31.0).
The use of both beta-blockers and ACE inhibitors/receptor
blockers was associated with an even lower mortality (16.6%; 95%
CI 13.3 to 20.0) than ACE inhibitor/receptor blockers alone
(22.3%; 95% CI 20.9 to 23.7).
The underutilization of effective therapy is not unique (6) even
for therapies such as these that have been repeatedly documented
to be beneficial in clinical trials that span over a decade (7). To
improve the utilization of beta-blockers and ACE inhibitors/
receptor blockers, their utilization has been flagged as a marker of
quality of care. Our study may provide some clues as to why
underutilization persists. Heart failure is not defined in terms of
preservation or loss of systolic function; rather, it is a clinical
constellation of symptoms (8). Both systolic and diastolic impair-
ment in HF are independently associated with increased mortality
risk (9). Clinical trials are not representative of the general
population with HF, as younger, male, white, and decreased
ejection-fraction patients are over-represented (10). The use of the
exclusion criteria of decreased ejection fraction has the effect of
under-recruitment of older female patients. In Alberta, seniors
(age 65 years and older) constituted about 85% of all new diagnoses
for HF during the study period (April 1, 1994, to March 31,
1999). Hospitalized patients age 75 years and older constituted
about 60% of all incident, prevalent, and total hospitalization cases
during this study period. In those age 75 years and older, women
constituted over 56% of hospitalized HF patients. The population
in Alberta was similar to that noted in the United States (10).
Thus, the reflective clinician may quite rightly question whether
clinical trial results are generalizable to the demographically
different population of hospitalized HF patients. Our study can
only associate decreased mortality to the use of beta-blockers and
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